{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MMR-II&page=3",
    "query": {
      "intervention": "MMR-II",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 65,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MMR-II&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MMR-II&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T09:36:58.841Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05239546",
      "title": "Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer",
        "dMMR Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-03-24",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Madison, Wisconsin",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05239546"
    },
    {
      "nct_id": "NCT02058563",
      "title": "Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rubella",
        "Mumps",
        "Measles"
      ],
      "interventions": [
        {
          "name": "Priorix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 996,
      "start_date": "2014-07-01",
      "completion_date": "2015-09-17",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058563"
    },
    {
      "nct_id": "NCT05870800",
      "title": "Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Colon Cancer",
        "Stage II Colon Cancer",
        "Stage III Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2025-06-15",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05870800"
    },
    {
      "nct_id": "NCT03257163",
      "title": "Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus Positive",
        "Gastric Adenocarcinoma",
        "Mismatch Repair Protein Deficiency",
        "Stage IB Gastric Cancer AJCC v7",
        "Stage II Gastric Cancer AJCC v7",
        "Stage IIA Gastric Cancer AJCC v7",
        "Stage IIB Gastric Cancer AJCC v7",
        "Stage III Gastric Cancer AJCC v7",
        "Stage IIIA Gastric Cancer AJCC v7",
        "Stage IIIB Gastric Cancer AJCC v7",
        "Stage IIIC Gastric Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2017-09-29",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03257163"
    },
    {
      "nct_id": "NCT00258726",
      "title": "Immune Responses to Two Dose Varivax +/- MMR-II",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Measles",
        "Mumps",
        "Rubella",
        "Varicella"
      ],
      "interventions": [
        {
          "name": "MMR-II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pro-Quad",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "12 Months to 12 Months"
      },
      "enrollment_count": 105,
      "start_date": "2005-10",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258726"
    },
    {
      "nct_id": "NCT02184572",
      "title": "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Measles; Mumps; Rubella",
        "Measles-Mumps-Rubella Vaccine"
      ],
      "interventions": [
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 1742,
      "start_date": "2014-08-25",
      "completion_date": "2015-12-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-07",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184572"
    },
    {
      "nct_id": "NCT04393454",
      "title": "Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic dMMR Solid Cancer",
        "Solid Tumor",
        "Cancer",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Sirolimus 2mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-11-16",
      "completion_date": "2023-05-16",
      "has_results": true,
      "last_update_posted_date": "2024-07-25",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04393454"
    },
    {
      "nct_id": "NCT00871117",
      "title": "Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tetanus",
        "Acellular Pertussis",
        "Diphtheria"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals'Kinrix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Merck and Company's MMRII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Merck and Company's Varivax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 478,
      "start_date": "2009-03-31",
      "completion_date": "2010-06-15",
      "has_results": true,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 11,
      "location_summary": "Antioch, California • Daly City, California • Hayward, California + 7 more",
      "locations": [
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871117"
    },
    {
      "nct_id": "NCT01000311",
      "title": "A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Disease"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP-IPV/Hib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HBV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "55 Days to 89 Days"
      },
      "enrollment_count": 529,
      "start_date": "2009-11",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01000311"
    },
    {
      "nct_id": "NCT06824194",
      "title": "Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Immunization"
      ],
      "interventions": [
        {
          "name": "PCV21 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 20 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxelis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAQTA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 2360,
      "start_date": "2025-02-18",
      "completion_date": "2027-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-21T09:36:58.841Z",
      "location_count": 103,
      "location_summary": "Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Oneonta",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06824194"
    }
  ]
}